AU2020281924B2 - Pyridopyrimidines derivatives as P2X3 inhibitors - Google Patents

Pyridopyrimidines derivatives as P2X3 inhibitors

Info

Publication number
AU2020281924B2
AU2020281924B2 AU2020281924A AU2020281924A AU2020281924B2 AU 2020281924 B2 AU2020281924 B2 AU 2020281924B2 AU 2020281924 A AU2020281924 A AU 2020281924A AU 2020281924 A AU2020281924 A AU 2020281924A AU 2020281924 B2 AU2020281924 B2 AU 2020281924B2
Authority
AU
Australia
Prior art keywords
pyrimidin
pyrido
amine
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020281924A
Other languages
English (en)
Other versions
AU2020281924A1 (en
Inventor
Charles Baker-Glenn
Matteo Biagetti
Paolo Bruno
Claudio FIORELLI
Roberta LANARO
Stephen David PENROSE
Hervè VAN DE POËL
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Publication of AU2020281924A1 publication Critical patent/AU2020281924A1/en
Application granted granted Critical
Publication of AU2020281924B2 publication Critical patent/AU2020281924B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020281924A 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as P2X3 inhibitors Active AU2020281924B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19177610 2019-05-31
EP19177610.3 2019-05-31
EP19201165.8 2019-10-02
EP19201165 2019-10-02
PCT/EP2020/064915 WO2020239953A1 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as p2x3 inhibitors

Publications (2)

Publication Number Publication Date
AU2020281924A1 AU2020281924A1 (en) 2021-12-16
AU2020281924B2 true AU2020281924B2 (en) 2026-04-16

Family

ID=70857198

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020281924A Active AU2020281924B2 (en) 2019-05-31 2020-05-28 Pyridopyrimidines derivatives as P2X3 inhibitors

Country Status (11)

Country Link
US (1) US12606562B2 (https=)
EP (1) EP3976609A1 (https=)
JP (1) JP7797204B2 (https=)
KR (1) KR102923602B1 (https=)
CN (1) CN114222741B (https=)
AU (1) AU2020281924B2 (https=)
BR (1) BR112021020279A2 (https=)
CA (1) CA3136024A1 (https=)
MA (1) MA56020A (https=)
MX (1) MX2021014116A (https=)
WO (1) WO2020239953A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
WO2022160931A1 (zh) * 2021-01-28 2022-08-04 浙江海正药业股份有限公司 吡啶并嘧啶类衍生物及其制备方法和用途
AR132737A1 (es) 2023-05-22 2025-07-23 Chiesi Farm Spa Proceso e intermedios para la preparación de un inhibidor p2x3

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
US20120122838A1 (en) * 2010-11-10 2012-05-17 Pingda Ren Heterocyclic compounds and uses thereof
CN106565684A (zh) * 2016-03-18 2017-04-19 南方医科大学 6‑吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
WO2018134685A2 (en) * 2017-01-17 2018-07-26 Liverpool School Of Tropical Medicine Compounds
WO2020020939A1 (en) * 2018-07-25 2020-01-30 Faes Farma, S.A. Pyridopyrimidines as histamine h4-receptor inhibitors

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
CA2557372C (en) 2004-03-05 2013-01-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
CN101300012B (zh) * 2005-09-01 2011-09-14 弗·哈夫曼-拉罗切有限公司 作为p2x3和p2x2/3调节剂的二氨基嘧啶类化合物在制备治疗呼吸系统疾病的药物中的应用
MX2008014689A (es) 2006-05-23 2008-11-27 Hoffmann La Roche Derivados de piridopirimidininona.
EP2038264B1 (en) 2006-06-29 2016-10-26 F.Hoffmann-La Roche Ag Tetrazole-substituted arylamides
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
PT2139334E (pt) 2007-04-17 2013-10-02 Evotec Ag Compostos heterocíclicos fusionados de 2-cianofenilo, e composições e utilizações dos mesmos
CA2715835C (en) 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
JP5608655B2 (ja) 2008-09-18 2014-10-15 エヴォテック アーゲー Ｐ２ｘ３受容体活性のモジュレーター
BRPI0919488A2 (pt) 2008-09-30 2015-12-01 Astrazeneca Ab composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
PL2399910T3 (pl) 2009-02-13 2014-09-30 Shionogi & Co Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je
WO2011041655A1 (en) * 2009-10-01 2011-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Quinazolin-4-amine derivatives; and methods of use
KR101685862B1 (ko) 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
WO2016053794A1 (en) 2014-09-30 2016-04-07 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
WO2016088838A1 (ja) 2014-12-04 2016-06-09 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
DK3355889T3 (da) 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
CA3029457A1 (en) 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
US11000491B2 (en) 2017-05-05 2021-05-11 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof
CN109721554A (zh) 2019-01-08 2019-05-07 贵州大学 一类4-氨基喹唑啉类化合物及其制备方法和应用
JP7797204B2 (ja) 2019-05-31 2026-01-13 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としてのピリドピリミジン誘導体
CA3139018A1 (en) 2019-05-31 2020-12-03 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4342007B2 (ja) * 1998-08-10 2009-10-14 大日本住友製薬株式会社 キナゾリン誘導体
US20120122838A1 (en) * 2010-11-10 2012-05-17 Pingda Ren Heterocyclic compounds and uses thereof
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
CN106565684A (zh) * 2016-03-18 2017-04-19 南方医科大学 6‑吡唑取代喹唑啉类化合物及其衍生物、合成方法及其应用
WO2018134685A2 (en) * 2017-01-17 2018-07-26 Liverpool School Of Tropical Medicine Compounds
WO2020020939A1 (en) * 2018-07-25 2020-01-30 Faes Farma, S.A. Pyridopyrimidines as histamine h4-receptor inhibitors

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
CANADIAN JOURNAL OF CHEMISTRY, 1967, vol. 45, no. 19, pages 2213 - 2216. *
CAS Registry Number 102393-82-8; STN Entry Date 26 May 1986 *
CAS Registry Number 1036738-12-1; STN Entry Date 28 July 2008 *
CAS Registry Number 1220518-09-1; STN Entry Date 27 April 2010 *
CAS Registry Number 1234616-70-6; STN Entry Date 3 August 2010 *
CAS Registry Number 1260665-43-7; STN Entry Date 27 January 2011 *
CAS Registry Number 20028-68-6; STN Entry Date 16 November 1984 *
CAS Registry Number 2143878-49-1; STN Entry Date 17 November 2017 *
CAS Registry Number 2379641-82-2; STN Entry Date 28 June 1991 *
CAS Registry Number 2387320-34-3; STN Entry Date 21 October 2014 *
CAS Registry Number 26850-60-2; STN Entry Date 16 November 1984 *
CAS Registry Number 303120-19-6, STN Entry Date 17 November 2000 *
CAS Registry Number 448204-55-5; STN Entry Date 9 September 2002 *
CAS Registry Number 74173-76-5; STN Entry Date 16 November 1984 *
CAS Registry Number 958360-30-0; STN Entry Date 17 December 2007 *
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, vol. 74, pages 65 - 72. *
International Journal of Molecular Sciences, 2015, vol. 16, no. 3, pages 5235-5253. *
Pulm Ther, 2022, 8:297-310. *

Also Published As

Publication number Publication date
JP2022534434A (ja) 2022-07-29
JP7797204B2 (ja) 2026-01-13
WO2020239953A1 (en) 2020-12-03
US20230212169A9 (en) 2023-07-06
US20220235060A1 (en) 2022-07-28
CN114222741A (zh) 2022-03-22
KR20220016074A (ko) 2022-02-08
US12606562B2 (en) 2026-04-21
MA56020A (fr) 2022-04-06
AU2020281924A1 (en) 2021-12-16
CA3136024A1 (en) 2020-12-03
MX2021014116A (es) 2021-12-10
EP3976609A1 (en) 2022-04-06
KR102923602B1 (ko) 2026-02-06
BR112021020279A2 (pt) 2021-12-14
CN114222741B (zh) 2025-12-30

Similar Documents

Publication Publication Date Title
AU2020281923B2 (en) Amino quinazoline derivatives as P2X3 inhibitors
AU2020281924B2 (en) Pyridopyrimidines derivatives as P2X3 inhibitors
EP4251273B1 (en) Phthalazine derivatives as p2x3 inhibitors
EP4251617B1 (en) (aza)quinoline 4-amines derivatives as p2x3 inhibitors
EP4251620B1 (en) Amino quinazoline derivatives as p2x3 inhibitors
RU2833037C2 (ru) Производные пиридопиримидинов в качестве ингибиторов p2x3
HK40060820A (zh) 作为p2x3抑制剂的吡啶并嘧啶类衍生物
HK40091208A (zh) 作为p2x3抑制剂的酞嗪衍生物